Tarsus Capital Stock from 2010 to 2024

TARS Stock  USD 46.40  0.18  0.39%   
Tarsus Pharmaceuticals Capital Stock yearly trend continues to be comparatively stable with very little volatility. Capital Stock will likely drop to 3,850 in 2024. Capital Stock is the total amount of a company's capital funded by shareholders through the issue and subscription of shares. View All Fundamentals
 
Capital Stock  
First Reported
2010-12-31
Previous Quarter
5.8 K
Current Value
3.9 K
Quarterly Volatility
1.7 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Tarsus Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tarsus Pharmaceuticals' main balance sheet or income statement drivers, such as Tax Provision of 0.0, Net Interest Income of 6.8 M or Depreciation And Amortization of 529.3 K, as well as many indicators such as Price To Sales Ratio of 35.81, Dividend Yield of 0.0 or PTB Ratio of 3.17. Tarsus financial statements analysis is a perfect complement when working with Tarsus Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Tarsus Pharmaceuticals Correlation against competitors.
For more information on how to buy Tarsus Stock please use our How to Invest in Tarsus Pharmaceuticals guide.

Latest Tarsus Pharmaceuticals' Capital Stock Growth Pattern

Below is the plot of the Capital Stock of Tarsus Pharmaceuticals over the last few years. It is the total amount of a company's capital funded by shareholders through the issue and subscription of shares. Tarsus Pharmaceuticals' Capital Stock historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Tarsus Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Capital Stock10 Years Trend
Slightly volatile
   Capital Stock   
       Timeline  

Tarsus Capital Stock Regression Statistics

Arithmetic Mean2,240
Geometric Mean1,724
Coefficient Of Variation77.89
Mean Deviation1,520
Median1,000.00
Standard Deviation1,745
Sample Variance3M
Range4.8K
R-Value0.84
Mean Square Error980,983
R-Squared0.70
Significance0.000099
Slope326.61
Total Sum of Squares42.6M

Tarsus Capital Stock History

2024 3850.0
2023 5750.0
2022 5000.0
2020 4000.0
2019 2000.0

Other Fundumenentals of Tarsus Pharmaceuticals

Tarsus Pharmaceuticals Capital Stock component correlations

0.980.98-0.87-0.810.740.650.650.991.01.01.01.00.960.740.82-0.490.61-0.49
0.981.0-0.86-0.750.680.580.491.00.980.980.980.980.960.790.75-0.440.53-0.44
0.981.0-0.85-0.750.680.580.511.00.980.980.980.980.960.760.78-0.410.55-0.41
-0.87-0.86-0.850.77-0.77-0.69-0.56-0.85-0.87-0.87-0.87-0.87-0.89-0.7-0.580.64-0.680.64
-0.81-0.75-0.750.77-0.99-0.97-0.68-0.78-0.8-0.81-0.78-0.81-0.7-0.49-0.890.87-0.930.87
0.740.680.68-0.77-0.990.990.660.710.740.750.710.750.640.440.83-0.920.95-0.92
0.650.580.58-0.69-0.970.990.650.610.650.660.620.660.540.330.8-0.940.97-0.94
0.650.490.51-0.56-0.680.660.650.520.650.660.630.660.550.260.72-0.490.66-0.49
0.991.01.0-0.85-0.780.710.610.520.990.980.980.980.960.770.8-0.460.57-0.46
1.00.980.98-0.87-0.80.740.650.650.991.01.01.00.960.750.82-0.490.6-0.49
1.00.980.98-0.87-0.810.750.660.660.981.01.01.00.960.730.83-0.490.62-0.49
1.00.980.98-0.87-0.780.710.620.630.981.01.01.00.970.760.79-0.470.57-0.47
1.00.980.98-0.87-0.810.750.660.660.981.01.01.00.960.730.83-0.490.62-0.49
0.960.960.96-0.89-0.70.640.540.550.960.960.960.970.960.660.68-0.410.51-0.41
0.740.790.76-0.7-0.490.440.330.260.770.750.730.760.730.660.45-0.290.25-0.29
0.820.750.78-0.58-0.890.830.80.720.80.820.830.790.830.680.45-0.580.79-0.58
-0.49-0.44-0.410.640.87-0.92-0.94-0.49-0.46-0.49-0.49-0.47-0.49-0.41-0.29-0.58-0.881.0
0.610.530.55-0.68-0.930.950.970.660.570.60.620.570.620.510.250.79-0.88-0.88
-0.49-0.44-0.410.640.87-0.92-0.94-0.49-0.46-0.49-0.49-0.47-0.49-0.41-0.29-0.581.0-0.88
Click cells to compare fundamentals

About Tarsus Pharmaceuticals Financial Statements

Tarsus Pharmaceuticals shareholders use historical fundamental indicators, such as Capital Stock, to determine how well the company is positioned to perform in the future. Although Tarsus Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in Tarsus Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on Tarsus Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Capital Stock5.8 K3.9 K
Issuance Of Capital Stock99.4 M83.9 M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Tarsus Stock Analysis

When running Tarsus Pharmaceuticals' price analysis, check to measure Tarsus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tarsus Pharmaceuticals is operating at the current time. Most of Tarsus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Tarsus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tarsus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Tarsus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.